GlycoNex Incorporation (4168.TWO)

TWD 26.0

(1.36%)

Market Cap (In TWD)

2.81 Billion

Revenue (In TWD)

2.54 Million

Net Income (In TWD)

-178.36 Million

Avg. Volume

499.74 Thousand

Currency
TWD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
24.0-31.85
PE
-
EPS
-
Beta Value
0.851
ISIN
TW0004168000
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Mei-Chun Yang
Employee Count
-
Website
https://www.glyconex.com.tw
Ipo Date
2012-06-20
Details
GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. The company's development pipeline for the treatment of solid tumors includes GNX102, a humanized monoclonal antibody, currently under phase 1 clinical stage; GNX201, an antibody drug currently under lead optimization stage; GNX202, an antibody drug currently under preclinical stage; and GNX203 and GNX204, antibody drugs currently under target validation stage. It is also involved in the development of SPD (Denosumab), a humanized IgG2 antibody that is in preclinical stage for the treatment of osteoporosis and oncology; and SEA (Aflibercept), a vascular endothelial growth factor binding fusion protein, currently under lead optimization stage for the treatment of ophthalmology and oncology. The company was incorporated in 2001 and is based in New Taipei City, Taiwan.